(openPR) Heidelberg, 30 August 2017 – Uncovering the molecular mechanism behind a rare genetic risk factor of Alzheimer’s disease points to a new therapeutic target.
---
A gene called triggering receptor expressed on myeloid cells 2, or TREM2, has been associated with numerous neurodegenerative diseases, such as Alzheimer's disease, Frontotemporal lobar degeneration, Parkinson's disease, and Nasu-Hakola disease. Recently, a rare mutation in the gene has been shown to increase the risk for developing Alzheimer’s disease. Independently from each other, two research groups have now revealed the molecular mechanism behind this mutation. Their research, published today in EMBO Molecular Medicine, sheds light on the role of TREM2 in normal brain function and suggests a new therapeutic target in Alzheimer's disease treatment.
Alzheimer’s disease, just like other neurodegenerative diseases, is characterized by the accumulation of specific protein aggregates in the brain. Specialized brain immune cells called microglia strive to counter this process by engulfing the toxic buildup. But as the brain ages, microglia eventually lose out and fail to rid all the damaging material.
TREM2 is active on microglia and enables them to carry out their protective function. The protein spans the microglia cell membrane and uses its external region to detect dying cells or lipids associated with toxic protein aggregates. Subsequently, TREM2 is cut in two. The external part is shed from the protein and released, while the remaining part still present in the cell membrane is degraded. To better understand TREM2 function, the two research groups took a closer look at its cleavage. They were led by Christian Haass at the German Center for Neurodegenerative Diseases at the Ludwig-Maximilians-Universität in Munich, Germany, and Damian Crowther of AstraZeneca’s IMED Neuroscience group in Cambridge, UK together with colleagues at the Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto and the Cambridge Institute for Medical Research, University of Cambridge, UK.
Using different technological approaches, both groups first determined the exact site of protein shedding and found it to be at amino acid 157. Amino acid 157 was no unknown. Only recently, researchers from China had uncovered that a mutation at this exact position, referred to as p.H157Y, increased the risk of Alzheimer’s disease. Together, these observations indicate that protein cleavage is perturbed in the p.H157 mutant and that this alteration promotes disease development.
As a next step, Haass and Crowther’s groups investigated the biochemical properties of the p.H157Y mutant protein more closely. They found that the mutant was cleaved more rapidly than a healthy version of the protein. “Our results provide a detailed molecular mechanism for how this rare mutation alters the function of TREM2 and hence facilitates the progression of Alzheimer’s disease,” said Crowther.
While most TREM2 mutations affect protein production, the mechanism behind p.H157Y is somewhat different. The p.H157Y mutation allows the protein to be correctly manufactured and transported to the microglia cell surface, but then it is cleaved too quickly. “The end result is the same. In both cases, there is too little full-length TREM protein on microglia,” said Haass. “This suggests that stabilizing TREM2, by making it less susceptible to cleavage, may be a viable therapeutic strategy.”
---------------------------
Information for editors:
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer’s disease-associated H157Y variant
P. Thornton, J. Sevalle, M.J. Deery, G. Fraser, Y. Zhou, S. Ståhl, E.H. Franssen, R.B. Dodd, S. Qamar, B. Gomez Perez-Nievas, L.S.C. Nicol, S. Eketjäll, J. Revell, C. Jones, A. Billinton, P. St George-Hyslop, I. Chessell & D.C. Crowther
EMBO Molecular Medicine, DOI 10.15252/emmm.201707673
An Alzheimer associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function
K. Schlepckow, G. Kleinberger, A. Fukumori, R. Feederle, S.F. Lichtenthaler, H. Steiner & C. Haass
EMBO Molecular Medicine, DOI 10.15252/emmm.201707672
About EMBO Press
EMBO Press stands for publishing impactful, high quality and reliable research across the biosciences in its four journals, The EMBO Journal, EMBO Reports, Molecular Systems Biology and EMBO Molecular Medicine.
EMBO Press pioneered the transparent editorial process in order to provide a rapid, fair and efficient publication process. Through developing and employing Source Data tools, EMBO Press works towards improving data transparency, reuse and discoverability. Through dedicated data integrity checks, it ensures the publication of reliable data. All submitted manuscripts are subject to scooping protection, which extends to manuscripts published on preprint servers. As a co-signatory of the San Francisco Declaration for Research Assessment, EMBO Press is an advocate for moving away from impact factors as a mechanism for research assessment.
About EMBO
EMBO is an organization of more than 1700 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European research environment where scientists can achieve their best work.
EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.
For more information: www.embo.org
Weitere Informationen:
- http://embo.org/news/press-releases/2017/stabilizing-trem2-a-potential-strategy-to-combat-alzheimer-s-disease
- http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201707673
- http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201707672
Quelle: idw
